TY - JOUR
T1 - Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents
T2 - A network meta-analysis of randomized controlled trials
AU - Garg, Aakash
AU - Rout, Amit
AU - Sharma, Abhishek
AU - Sargsyan, Davit
AU - Beavers, Traymon
AU - Tantry, Udaya
AU - Gurbel, Paul
AU - Rao, Sunil V.
AU - Kostis, John B.
AU - Cohen, Marc
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Aims: We aimed to determine the efficacy and safety of different anti-platelet regimens after percutaneous coronary intervention (PCI) with drug eluting stent (DES) implantation using a network meta-analysis of randomized controlled trials (RCTs). Methods: RCTs comparing shorter duration (≤6 months) of dual antiplatelet therapy (S-DAPT) with either aspirin (ASA) or P2Y12 inhibitor monotherapy against longer duration (≥12 months) DAPT (L-DAPT) after PCI were searched in the MEDLINE, EMBASE and COCHRANE databases. End-points of interest were all-cause death, cardiovascular (CV) death, myocardial infarction (MI), stent thrombosis (ST), major bleeding and major or minor bleeding. Network meta-analyses were performed using frequentist approach. Results: Eighteen RCTs with total of 57,942 patients met the inclusion and exclusion criteria. This included 14 RCTs (N = 28,853) of S-DAPT with ASA monotherapy and 4 RCTs (N = 29,089) with P2Y12 inhibitor monotherapy. Compared with L-DAPT, the odds of MI were higher with S-DAPT with ASA monotherapy [OR 1.23; 95% CI 1.01–1.48], but not with P2Y12 inhibitor monotherapy [0.98; 0.85–1.14]. Both S-DAPT regimens lowered rates of major bleeding when compared with L-DAPT; ASA monotherapy [0.70; 0.49–1.00] and P2Y12 monotherapy [0.67; 0.45–0.98]. There were no differences in risks of all-cause or CV death between either regimen of S-DAPT and L-DAPT. However, in the acute coronary syndrome subgroup, ASA monotherapy was associated with increased risk of ST [1.55; 1.021–2.36] but P2Y12 monotherapy was not [0.93; 0.58–1.48]. Conclusion: Amongst patients undergoing DES implantation, S-DAPT with P2Y12 inhibitor monotherapy reduces bleeding without increased risk of MI or ST compared with L-DAPT. Prospective trials are needed to evaluate if S-DAPT with P2Y12 monotherapy is superior to S-DAPT with ASA monotherapy for ischemic protection.
AB - Aims: We aimed to determine the efficacy and safety of different anti-platelet regimens after percutaneous coronary intervention (PCI) with drug eluting stent (DES) implantation using a network meta-analysis of randomized controlled trials (RCTs). Methods: RCTs comparing shorter duration (≤6 months) of dual antiplatelet therapy (S-DAPT) with either aspirin (ASA) or P2Y12 inhibitor monotherapy against longer duration (≥12 months) DAPT (L-DAPT) after PCI were searched in the MEDLINE, EMBASE and COCHRANE databases. End-points of interest were all-cause death, cardiovascular (CV) death, myocardial infarction (MI), stent thrombosis (ST), major bleeding and major or minor bleeding. Network meta-analyses were performed using frequentist approach. Results: Eighteen RCTs with total of 57,942 patients met the inclusion and exclusion criteria. This included 14 RCTs (N = 28,853) of S-DAPT with ASA monotherapy and 4 RCTs (N = 29,089) with P2Y12 inhibitor monotherapy. Compared with L-DAPT, the odds of MI were higher with S-DAPT with ASA monotherapy [OR 1.23; 95% CI 1.01–1.48], but not with P2Y12 inhibitor monotherapy [0.98; 0.85–1.14]. Both S-DAPT regimens lowered rates of major bleeding when compared with L-DAPT; ASA monotherapy [0.70; 0.49–1.00] and P2Y12 monotherapy [0.67; 0.45–0.98]. There were no differences in risks of all-cause or CV death between either regimen of S-DAPT and L-DAPT. However, in the acute coronary syndrome subgroup, ASA monotherapy was associated with increased risk of ST [1.55; 1.021–2.36] but P2Y12 monotherapy was not [0.93; 0.58–1.48]. Conclusion: Amongst patients undergoing DES implantation, S-DAPT with P2Y12 inhibitor monotherapy reduces bleeding without increased risk of MI or ST compared with L-DAPT. Prospective trials are needed to evaluate if S-DAPT with P2Y12 monotherapy is superior to S-DAPT with ASA monotherapy for ischemic protection.
KW - Drug eluting stents
KW - Dual anti-platelet therapy
KW - Percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=85083335520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083335520&partnerID=8YFLogxK
U2 - 10.1016/j.pcad.2020.03.018
DO - 10.1016/j.pcad.2020.03.018
M3 - Review article
C2 - 32247786
AN - SCOPUS:85083335520
SN - 0033-0620
VL - 63
SP - 243
EP - 248
JO - Progress in Cardiovascular Diseases
JF - Progress in Cardiovascular Diseases
IS - 3
ER -